Review



human sbac cell line hutu80  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ATCC human sbac cell line hutu80
    Figure 1. Metformin inhibits <t>HuTu80</t> cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).
    Human Sbac Cell Line Hutu80, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 186 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+sbac+cell+line+hutu80/HuTu+80/pm28440424-29-1-10
    Average 95 stars, based on 186 article reviews
    human sbac cell line hutu80 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma."

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    Journal: International journal of oncology

    doi: 10.3892/ijo.2017.3971

    Figure 1. Metformin inhibits HuTu80 cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).
    Figure Legend Snippet: Figure 1. Metformin inhibits HuTu80 cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).

    Techniques Used: Control

    Figure 2. Metformin blocks cell cycle progression at the G0/G1 phase. (A) Flow cytometric analysis of proliferating HuTu80 cells, 24, 48 and 72 h after administration of 10 mM metformin (Met). (B) Metformin increased the proportion of cells in the G0/G1 phase in the treated cells (Student's t-test, **p<0.01 n=3, error bars represent the SD). The proportion of cells in S phase and G2/M phase decreased accordingly.
    Figure Legend Snippet: Figure 2. Metformin blocks cell cycle progression at the G0/G1 phase. (A) Flow cytometric analysis of proliferating HuTu80 cells, 24, 48 and 72 h after administration of 10 mM metformin (Met). (B) Metformin increased the proportion of cells in the G0/G1 phase in the treated cells (Student's t-test, **p<0.01 n=3, error bars represent the SD). The proportion of cells in S phase and G2/M phase decreased accordingly.

    Techniques Used:

    Figure 4. Metformin reduces the expression of phosphorylated EGFR and ROR2. (A) The template indicates locations of tyrosine kinase antibodies spotted onto a human phospho-RTK array. (B) Representative expression of various phosphorylated tyrosine kinase receptors in HuTu80 cells with or without 5 mM metformin for 48 h. (C) The densitometric ratios of the EGFR, and ROR2 spots were 57 and 75%, respectively (the ratio of metformin-treated cells to control cells).
    Figure Legend Snippet: Figure 4. Metformin reduces the expression of phosphorylated EGFR and ROR2. (A) The template indicates locations of tyrosine kinase antibodies spotted onto a human phospho-RTK array. (B) Representative expression of various phosphorylated tyrosine kinase receptors in HuTu80 cells with or without 5 mM metformin for 48 h. (C) The densitometric ratios of the EGFR, and ROR2 spots were 57 and 75%, respectively (the ratio of metformin-treated cells to control cells).

    Techniques Used: Expressing, Control

    Figure 3. Metformin reduces cell cycle regulatory proteins and activates the AMPKα pathway. (A) Western blot analysis of cyclin D1, cyclin E, Cdk2, Cdk4, Cdk6, Rb, pRb in HuTu80 cells treated with 10 mM metformin for 24-72 h. The expression level of cyclin D1, cyclin E, Cdk4 and pRb decreased in treated cells. (B) Metformin increased p-AMPKα after a 24-h treatment with 10 mM metformin. p-mTOR and p-p70s6k, downstream of AMPKα, decreased accord- ingly in treated cells. There were no substantial differences in total AMPK, mTOR or p70s6k expression between metformin-treated cells and the control cells.
    Figure Legend Snippet: Figure 3. Metformin reduces cell cycle regulatory proteins and activates the AMPKα pathway. (A) Western blot analysis of cyclin D1, cyclin E, Cdk2, Cdk4, Cdk6, Rb, pRb in HuTu80 cells treated with 10 mM metformin for 24-72 h. The expression level of cyclin D1, cyclin E, Cdk4 and pRb decreased in treated cells. (B) Metformin increased p-AMPKα after a 24-h treatment with 10 mM metformin. p-mTOR and p-p70s6k, downstream of AMPKα, decreased accord- ingly in treated cells. There were no substantial differences in total AMPK, mTOR or p70s6k expression between metformin-treated cells and the control cells.

    Techniques Used: Western Blot, Expressing, Control

    Figure 6. Metformin inhibits tumor growth in vivo. When tumors became pal- pable, 0 or 1 mg of metformin was injected intraperitoneally 5 times per week for 2 weeks. (A) Representative images of the gross HuTu80 tumors treated with metformin, or of the control. (B) The tumor volume was calculated as [tumor length (mm) x tumor width (mm)2]/2. The tumors were significantly smaller in the metformin-treated group than in the control group. Each point represents the mean ± standard deviation of 8 mice (**p<0.01, by two-way ANOVA).
    Figure Legend Snippet: Figure 6. Metformin inhibits tumor growth in vivo. When tumors became pal- pable, 0 or 1 mg of metformin was injected intraperitoneally 5 times per week for 2 weeks. (A) Representative images of the gross HuTu80 tumors treated with metformin, or of the control. (B) The tumor volume was calculated as [tumor length (mm) x tumor width (mm)2]/2. The tumors were significantly smaller in the metformin-treated group than in the control group. Each point represents the mean ± standard deviation of 8 mice (**p<0.01, by two-way ANOVA).

    Techniques Used: In Vivo, Injection, Control, Standard Deviation

    Figure 7. Hierarchical clustering of HuTu80 cells with or without metformin. HuTu80 cells were clustered according to the expression profiles of 50 miRNAs differentially expressed by HuTu80 cells with or without metformin. The analyzed samples are shown in the columns, and the miRNAs are shown in the rows. The miRNA clustering color scale shown at the top indicates the relative expression levels of miRNAs; with red and blue representing high and low expression levels, respectively.
    Figure Legend Snippet: Figure 7. Hierarchical clustering of HuTu80 cells with or without metformin. HuTu80 cells were clustered according to the expression profiles of 50 miRNAs differentially expressed by HuTu80 cells with or without metformin. The analyzed samples are shown in the columns, and the miRNAs are shown in the rows. The miRNA clustering color scale shown at the top indicates the relative expression levels of miRNAs; with red and blue representing high and low expression levels, respectively.

    Techniques Used: Expressing

    Related Articles

    Control:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.

    Expressing:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.

    Western Blot:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.

    In Vivo:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.

    Injection:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.

    Standard Deviation:

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
    Article Snippet: Cell lines, reagents and antibodies.Cell lines, reagents and antibodies.. The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (533-69545; wako, Osaka, Japan), and penicillin/streptomycin (100 mg/l; Invitrogen, Tokyo, Japan) in a 5% CO2 atmosphere at 37 ̊C.



    Similar Products

    human sbac cell line hutu80  (ATCC)
    95
    ATCC human sbac cell line hutu80
    Figure 1. Metformin inhibits <t>HuTu80</t> cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).
    Human Sbac Cell Line Hutu80, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+sbac+cell+line+hutu80/HuTu+80/pm28440424-29-1-10
    Average 95 stars, based on 1 article reviews
    human sbac cell line hutu80 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Metformin inhibits HuTu80 cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 1. Metformin inhibits HuTu80 cell proliferation. (A) HuTu80 cells (5,000/well) were seeded in 96-well plates. After 24 h, the culture medium was replaced with fresh culture medium containing 0, 1, 5 or 10 mM metformin. Cell viability was assayed after 48 h. The results show that 5 and 10 mM metformin significantly inhibited cell proliferation (Student's t-test, **p<0.01 n=8, error bars represent the SD). (B) Cell viability was assayed daily from 0 to 72 h. The viability of metformin-treated cells differed significantly in a time- and dose-dependent manner from the control cells (**p<0.01, by two-way ANOVA).

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Control

    Figure 2. Metformin blocks cell cycle progression at the G0/G1 phase. (A) Flow cytometric analysis of proliferating HuTu80 cells, 24, 48 and 72 h after administration of 10 mM metformin (Met). (B) Metformin increased the proportion of cells in the G0/G1 phase in the treated cells (Student's t-test, **p<0.01 n=3, error bars represent the SD). The proportion of cells in S phase and G2/M phase decreased accordingly.

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 2. Metformin blocks cell cycle progression at the G0/G1 phase. (A) Flow cytometric analysis of proliferating HuTu80 cells, 24, 48 and 72 h after administration of 10 mM metformin (Met). (B) Metformin increased the proportion of cells in the G0/G1 phase in the treated cells (Student's t-test, **p<0.01 n=3, error bars represent the SD). The proportion of cells in S phase and G2/M phase decreased accordingly.

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques:

    Figure 4. Metformin reduces the expression of phosphorylated EGFR and ROR2. (A) The template indicates locations of tyrosine kinase antibodies spotted onto a human phospho-RTK array. (B) Representative expression of various phosphorylated tyrosine kinase receptors in HuTu80 cells with or without 5 mM metformin for 48 h. (C) The densitometric ratios of the EGFR, and ROR2 spots were 57 and 75%, respectively (the ratio of metformin-treated cells to control cells).

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 4. Metformin reduces the expression of phosphorylated EGFR and ROR2. (A) The template indicates locations of tyrosine kinase antibodies spotted onto a human phospho-RTK array. (B) Representative expression of various phosphorylated tyrosine kinase receptors in HuTu80 cells with or without 5 mM metformin for 48 h. (C) The densitometric ratios of the EGFR, and ROR2 spots were 57 and 75%, respectively (the ratio of metformin-treated cells to control cells).

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Expressing, Control

    Figure 3. Metformin reduces cell cycle regulatory proteins and activates the AMPKα pathway. (A) Western blot analysis of cyclin D1, cyclin E, Cdk2, Cdk4, Cdk6, Rb, pRb in HuTu80 cells treated with 10 mM metformin for 24-72 h. The expression level of cyclin D1, cyclin E, Cdk4 and pRb decreased in treated cells. (B) Metformin increased p-AMPKα after a 24-h treatment with 10 mM metformin. p-mTOR and p-p70s6k, downstream of AMPKα, decreased accord- ingly in treated cells. There were no substantial differences in total AMPK, mTOR or p70s6k expression between metformin-treated cells and the control cells.

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 3. Metformin reduces cell cycle regulatory proteins and activates the AMPKα pathway. (A) Western blot analysis of cyclin D1, cyclin E, Cdk2, Cdk4, Cdk6, Rb, pRb in HuTu80 cells treated with 10 mM metformin for 24-72 h. The expression level of cyclin D1, cyclin E, Cdk4 and pRb decreased in treated cells. (B) Metformin increased p-AMPKα after a 24-h treatment with 10 mM metformin. p-mTOR and p-p70s6k, downstream of AMPKα, decreased accord- ingly in treated cells. There were no substantial differences in total AMPK, mTOR or p70s6k expression between metformin-treated cells and the control cells.

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Western Blot, Expressing, Control

    Figure 6. Metformin inhibits tumor growth in vivo. When tumors became pal- pable, 0 or 1 mg of metformin was injected intraperitoneally 5 times per week for 2 weeks. (A) Representative images of the gross HuTu80 tumors treated with metformin, or of the control. (B) The tumor volume was calculated as [tumor length (mm) x tumor width (mm)2]/2. The tumors were significantly smaller in the metformin-treated group than in the control group. Each point represents the mean ± standard deviation of 8 mice (**p<0.01, by two-way ANOVA).

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 6. Metformin inhibits tumor growth in vivo. When tumors became pal- pable, 0 or 1 mg of metformin was injected intraperitoneally 5 times per week for 2 weeks. (A) Representative images of the gross HuTu80 tumors treated with metformin, or of the control. (B) The tumor volume was calculated as [tumor length (mm) x tumor width (mm)2]/2. The tumors were significantly smaller in the metformin-treated group than in the control group. Each point represents the mean ± standard deviation of 8 mice (**p<0.01, by two-way ANOVA).

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: In Vivo, Injection, Control, Standard Deviation

    Figure 7. Hierarchical clustering of HuTu80 cells with or without metformin. HuTu80 cells were clustered according to the expression profiles of 50 miRNAs differentially expressed by HuTu80 cells with or without metformin. The analyzed samples are shown in the columns, and the miRNAs are shown in the rows. The miRNA clustering color scale shown at the top indicates the relative expression levels of miRNAs; with red and blue representing high and low expression levels, respectively.

    Journal: International journal of oncology

    Article Title: Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.

    doi: 10.3892/ijo.2017.3971

    Figure Lengend Snippet: Figure 7. Hierarchical clustering of HuTu80 cells with or without metformin. HuTu80 cells were clustered according to the expression profiles of 50 miRNAs differentially expressed by HuTu80 cells with or without metformin. The analyzed samples are shown in the columns, and the miRNAs are shown in the rows. The miRNA clustering color scale shown at the top indicates the relative expression levels of miRNAs; with red and blue representing high and low expression levels, respectively.

    Article Snippet: The human SBAC cell line HuTu80 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

    Techniques: Expressing